Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Haploidentical NK Cells and IL-2 in HIV
NCT03346499Phase 1Completed
- Sponsor
- University of Minnesota
- Start
- Mar 2017
- Primary completion
- Nov 2018
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of haploidentical natural killer cells in human immunodeficiency virus infection (HIV), sponsored by University of Minnesota. Primary endpoints: Safety of administration of haploidentical NK cells in HIV infected individuals - Adverse Events at 100 days and Tolerability of administration of haploidentical NK cells in HIV infected individuals- Side effects at 100 days. Started Mar 2017; status: completed.
02
Drugs
haploidentical natural killer cells
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03346499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03346499.